In this chapter of Cancer 360 the journalist Adam Martín talks to 8 professionals from VHIO who work in different…
NOTICIAS
On April 3, the VII National Medicine Awards organized by the magazine El Suplemento were presented. Dr. Josep Tabernero, director…
Results of the multi-center iPROMET study identify whole-body magnetic resonance imaging as a biomarker of response in prostate cancer patients…
Developed by VHIO’s Radiomics Group in close collaboration with researchers of the Neuro-Radiology Unit at the Bellvitge University Hospital (HUB),…
The predictability of response criteria remains controversial in drug development. Numerous reviews and meta-analyses continue to question the reliability of…
Josep Tabernero, Director of VHIO, has been awarded as a Fellow of the American Society of Clinical Oncology (FASCO). This…
Recently published in Nature Protocols, VHIO’s Francisco Barriga and co-author Scott W. Lowe at the Memorial Sloan Kettering Cancer Center,…
Recently published in the journal Nature Medicine (1), results of exploratory research from the open-label phase III INTRIGUE clinical trial…
The Vall d’Hebron Institute of Oncology (VHIO) has received 52 grants this year for its research and technical staff that…
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
